OneMedRadio

Greenestone Healthcare Corp. CEO Discusses Valuation for Canadian Medical Clinics

June 26, 2013 OneMedPlace Team 0

GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon spoke with OneMedRadio about market opportunity for clinics in the unique Canadian healthcare system, and evolving valuation drivers in this space.

Aptiv Solutions Executive Discusses the State of Mobile Health Technology Regulatory

June 23, 2013 OneMedPlace Team 0

OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.

Functional Neuromodulation CEO: Deep Brain Stimulation a Treatment for Alzheimer’s Disease

June 18, 2013 OneMedPlace Team 0

Charlottesville, VA-based Functional Neuromodulation is conducting an advanced trial of the application of Deep Brain Stimulation (DBS) therapy as a supplement for current Alzheimer’s Disease treatments. OneMedRadio’s Matt Margolis spoke with Dan O’Connell, co-founder and CEO of Functional Neuromodulation, about the science behind applying Deep Brain Stimulation to Alzheimer’s Disease, its current clinical trial, the lack of venture capital for Alzheimer’s research, and the regulatory obstacles that Functional Neuromodulation will face in the future.

ISTO Technologies CFO: No Other Company Can Grow Living Cartilage in a Lab Setting

April 30, 2013 OneMedPlace Team 0

ISTO Technologies has a unique pipeline that has demonstrated both clinical progress and market success. With one commercialized product — a bone graft extender and substitute — and two late-stage clinical programs focusing in engineering cartilage tissue for knee and back, respectively, the company is poised to capture an opportunistic yet untapped market. OneMedRadio spoke with CFO Scott Gill about market opportunity, and finding success in a notoriously unfriendly space.

Idrasil: The First Medical Marijuana Pill, and Parallels in Opiate Market

April 24, 2013 OneMedPlace Team 0

California-based C3 International has brought to market the first medical marijuana pill, known as Idrasil. OneMedRadio spoke with C3 International Chairman Steele Clarke Smith III about the unique delivery technology behind Idrasil, and trends in the sector related to market opportunity, necessity for non-inhaled delivery and dialogue in the medical community.

Caprion’s Proteomic Biomarkers — Diverse Clientele Leads to In-House Pipeline

April 16, 2013 OneMedPlace Team 0

Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.

OneMedRadio: Del Mar Pharmaceuticals CEO Discusses the Public Market, Glioblastoma and Orphan Drugs

April 5, 2013 OneMedPlace Team 0

Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.

Glysure CEO Discusses Real-Time Glucose Monitoring Technology, ISO 13485 Certification and CE Mark

March 18, 2013 OneMedPlace Team 0

As part of our expert series on the state of the industry, OneMedRadio spoke with Glysure CEO Chris Jones to discuss this recent news and learn about this unique technology. Jones also discussed trends in the industry affecting company growth and investment strategy, including reimbursement issues, evolving exit strategy, and the move away from normative medicine.